Rheumatoid arthritis (RA) is a chronic debilitating disease characterized by distinct autoimmune, inflammatory and fibrovascular components which lead to synovial proliferation and joint destruction. However, existing treatments specifically target only autoimmune and inflammatory components despite the fact that neovascularization of the inflamed synovium is a hallmark of rheumatoid arthritis. Angiogenesis may contribute to synovial growth, leukocyte recruitment and tissue remodeling, thus potentiating disease progression. Although no therapies currently target angiogenesis, several existing therapies have anti-angiogenic activity. Recent advances in anti-angiogenic strategies in oncology, including the identification of integrin avß3 as a crucial effector of angiogenesis, suggest a means to assess the role of angiogenesis in rheumatoid arthritis. Synovial endothelial cells have been shown to express integrin avß3, suggesting that these cells may be targeted for angiogenesis inhibition. Prior studies in rat arthritis models have shown benefit after the addition of broad spectrum integrin antagonists. However, formal assessment of integrin-targeted anti-angiogenic activity is now underway. These controlled studies will be important in assessing the efficacy of therapies which target angiogenesis in RA.
Introduction
Rheumatoid arthritis (RA) is a complex chronic inflammatory disease which affects approximately 1-3% of the general population. The disease has several complementary yet distinct components, including autoimmune, inflammatory and fibrovascular responses, which contribute to the significant morbidity and mortality associated with advanced disease (1, 2) . Currently, a conclusive etiology is lacking, but after an initiating insult, autoimmunity is triggered in a genetically predisposed individual. The resultant articular pathology is characterized by inflammation and proliferation of the synovial lining, resulting in the generation of interdigitating folds of tissue, termed pannus (3) . The pannus is a major site of ongoing inflammation and protease production, and is thought to be central to the development of cartilage and bone-erosive disease which leads to the destruction of joint architecture (3) (4) (5) .
A variety of anti-inflammatory and immunosuppressive regimens have been employed to limit disease. However, significant toxicity is associated with current therapies which subdue but ultimately fail to stop progression to erosive joint destruction. Clearly, further modes of intervention for RA are needed. In this regard, the extensive synovial neovasculature, which is one of the earliest histopathologic findings and a hallmark of RA (6, 7) , has been suggested as an attractive target for therapy. Importantly, many of the therapies currently in use including gold (8) , sulfonamides (9) , chloroquine (10), methotrexate (11) , penicillamine (12) , and COX inhibitors (13) have retrospectively been found to possess anti-angiogenic activity either in vivo or in vitro. However, previous examination of angiogenesis inhibition as a primary therapeutic approach in RA is limited (14, 15) , and presently there are no drugs specifically targeted at preventing the subsynovial vascularization which characterizes this disease.
Angiogenesis as a propagating factor in RA
Angiogenesis, the coordinated growth of new blood vessels from pre-existing vasculature, occurs physiologically during reproductive and developmental processes as well as during the late phases of wound healing following tissue damage. However, inappropriate or aberrant angiogenesis is associated with a variety of diseases, including tumor growth and metastasis as well as fibrovascular disorders such as psoriasis, diabetic retinopathy and RA (16) . In fact, the invasive growth of pannus tissue in RA has been compared to that of neoplastic tumors, and it has been suggested that the pannus itself may be considered a form of benign tumor (17) . The recent successes of anti-angiogenic therapies in controlling tumor growth provide a strong rationale to investigate these agents as potential new strategies to limit pannus growth and joint destruction in RA.
Angiogenesis has been suggested to be central to the pathophysiology of RA, contributing to disease progression at multiple levels (6, 7) . The most obvious role of vascularization during RA is an increased capacity to sustain the nutritional and metabolic requirements of the hyperproliferating synovium and invading pannus (3) (4) (5) . However, it is clear that the neovascularization which is ultimately achieved is not completely sufficient to relieve the intra-articular hypoxia associated with RA (18) , resulting in a chronic angiogenic response.
In part, this is likely due to the distinction that in RA angiogenesis occurs within the context of an ongoing autoimmune reaction, where leukocyte extravasation into the tissues serves to maintain a local inflammatory response. Neovascularization, and the resulting increased vascular bed volume, directly permit increased recruitment of bloodborne leukocytes into the synovial tissue. In turn, these activated leukocytes release angiogenic cytokines (see below) but also cause local microvascular occlusion and injury. Further damage to endothelial cells occurs directly via the release of high levels of reactive oxygen species and proteolytic enzymes (19) . In turn, local vessel damage will subsequently induce a reparative angiogenic response from adjacent or contiguous vessels. Thus, the synovial vasculature is not static, but undergoes dynamic reorganization in response to cumulative cycles of endothelial proliferation and death (18) .
A direct role for endothelial cells in articular remodeling
Recent investigations have revealed that activated endothelial cells may make direct contributions to both ongoing inflammation and protease production. The increased endothelial mass in RA can function as a rich source of inflammatory cytokines including IL-1, IL-6 and IL-8, as well as both vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) (reviewed in 6,7). Importantly, many of these cytokines produced are themselves angio-genic, providing a direct autocrine mechanism to sustain neovascularization of the subsynovial tissue (20) . Alternatively, many cytokines present in synovial tissues play an indirect role in neovascularization by stimulating the secretion of directly angiogenic cytokines from either inflammatory or bystander cell populations, while selected cytokines have both activities (Table 1) . For example, in addition to angiogenic effects on endothelial cells, the production of VEGF and bFGF also serves to activate cells of the macrophage (21) and fibroblast (22) lineages, respectively. Interestingly, these two lineages are the predominant components of the hyperproliferative synovial lining, and comprise a significant proportion of the pannus in RA.
Early responses of the endothelium to angiogenic cytokines include the initiation of vascular permeability and subsequently the upregulation of protease production. These events result in significant alteration of the composition of the local extracellular matrix (ECM). Numerous proteases including urokinase, tissue plasminogen activator and the metalloproteinases MMP-1, 2, 3, and 9 are produced by activated endothelial cells (5) (6) (7) (8) 23) . The metalloproteinases are capable of digesting subendothelial basement matrix, particularly collagen types IV and V, which act to suppress the angiogenic phenotype (14, 24, 25) . The combined proteolysis and vascular permeability not only eliminates the capacity of these collagens to inhibit angiogenesis, but additionally provides a new provisional ECM to sustain endothelial survival (26) and migration (27) . Plasma glycoproteins including fibrinogen and fibronectin polymerize extravascularly (28) and probably also on the luminal face of the endothelium (29) , similar to normal wound healing responses. However, unlike wound healing, the deposited provisional matrix is not effectively remodeled and replaced in RA. In fact, evidence suggests that the deposition of this provisional ECM is sustained (30, 31) , and actually contributes to arthritic disease severity (31) .
In this respect, components of the provisional ECM are potent cell activators. Fibronectin, vitronectin and fibrinogen can be chemotactic or haptotactic substrates for endothelial cells (32) (33) (34) (35) . The principal receptors involved in endothelial attachment to, and migration on, these substrates are integrins, a family of heterodimeric (a/ß) transmembrane adhesion receptors (36) . Although the integrins have no intrinsic kinase activity, it has become clear that integrin- The invasive phenotype appears to provide a selective target for antagonist activity in vivo. Immunohistochemical examination of tumor fragments implanted in either human skin xenograft or on chick CAM revealed necrotic areas associated with reduced vascularity and obvious disruption of the tumor-associated vasculature (45) . TUNEL staining revealed the presence of apoptotic blood vessels in tumor-associated vasculature, yet no apoptosis was observed in adjacent uninvolved tissues. Thus, although integrin antagonists are potent inhibitors of angiogenesis, no effect is apparent on quiescent endothelium. Cryosections of human RA synovium were stained with monoclonal antibody LM609, specific for integrin avß3, and detected with secondary rhodamine-conjugated donkey anti-mouse (avß3) (red). Sections were costained with goat polyclonal antisera to von Willebrand factor and detected with secondary FITC-conjugated donkey antigoat antisera (vWf) to reveal mature blood vessels (green). The colocalization of the signals is revealed when the fluorescent channels are combined (Merge, yellow) (400X). Note that many early microvessels, which do not yet stain for wWf, stain selectively for integrin avß3.
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Targeting integrins in arthritis
Integrin avß3 is highly expressed on the synovial endothelium in RA (50, 51) , as identified by costaining for von Willebrand factor, an endothelial cell marker (Figure 2) . Studies in our laboratory have revealed that integrin avß3 is also upregulated on vascular cells in a rabbit antigen-induced arthritis (AIA) model (52) . This model resembles human disease histopathologically, including neovascularization, synovial hypertrophy and subsynovial inflammatory infiltrate, and presented a unique opportunity to demonstrate specifically the impact of integrin-based anti-angiogenic therapy in arthritis.
Previously, integrin antagonists derived from fragments of the fibronectin cell-binding domain have been demonstrated to inhibit the development of arthritis in a rat model of disease (53) . The activity of these peptides has been attributed to their capacity to block the activity of ß1 integrins, and therefore it was proposed that decreased arthritis resulted from the prevention of autoimmune/proinflammatory cell recruitment into the synovium. Similar peptides prevent inflammation in delayed-type hypersensitivity reactions through this mechanism (54) . However, it is noteworthy that these linear peptide antagonists have broad specificity, and actually inhibit integrin avß3-dependent adhesion at lower concentrations than, for example, integrin a5ß1-mediated adhesion (55) . This raises the possibility that some of the observed anti-arthritic activity resulted from anti-angiogenic effects. In order to address these types of questions, antagonists with higher specificity/selectivity will be required. Since the principal target of novel cyclic av antagonists used in tumor studies appears to be endothelial cells expressing avß3, these compounds may be amenable to future studies on RA (46) . The success of alternative, toxin-based anti-angiogenic strategies such as taxol (14) or derivatives of the fungal metabolite fumagillin (15) validates targeting endothelial cell-mediated pathology in RA. Together, these studies provide an excellent rationale to pursue development of integrin-based anti-angiogenic strategies as a viable approach to control RA. PEX as an alternative antagonist of integrin avß3 in angiogenesis
Incorporated themes in future antiangiogenic strategies
Since cellular responses to cytokines and other soluble factors occur within the governing context of the ECM, modulation of these responses through the antagonism of adhesion receptors is becoming increasingly attractive as a therapy. Increased efficacy may be achieved by alternative approaches, including systemic administration of stable antagonists or possibly local gene delivery allowing regional production of anti-angiogenic proteins for extended periods. Angiogenesis is influenced by an ever-growing list of proteins, protein fragments, peptides, sugars and lipids, but a common element in the angiogenic response induced by any means is the local reorganization of the ECM. Toward this end, a second strategy developed for the control of angiogenesis combines antagonism of avß3 with prevention of ECM alteration. The recent discovery that integrin avß3 binding to MMP-2 is mediated via the hemopexin domain of MMP-2 (PEX) (56) has led to the development of recombinant PEX as a coordinate inhibitor of integrin function and MMP-2 activation in vitro. As might be predicted from these results, PEX also blocks angiogenesis in vivo (Figure 3 ) (56) , suggesting that future identification of key sequences in PEX may provide additional multifunctional angiogenesis inhibitors.
Enhanced control of angiogenic responses may be possible by coordinately inhibiting complementary potentiating events involved in neovascularization. In the case of RA, the ongoing inflammatory component presents an obvious and important target (57) , since angiogenesis and inflammation are complementary events contributing to disease progression. This type of logical combination therapy, in which both ongoing neovascularization and inflammation are targeted as distinct but inter-related components, may offer the most effective means of treatment for rheumatoid arthritis. Recent studies focusing on the interactions of cells with the ECM have led to advances in both angiogenesis and inflammation research, providing valuable tools for future investigations. Ultimately, an increased understanding of the pathological mechanisms in RA will permit development of new and innovative therapies.
